Commissioned and funded by Daiichi Sankyo
The production of this Guidelines card has been commissioned and funded by Daiichi Sankyo UK.View Bempedoic acid (Nilemdo®▼) & Bempedoic acid and ezetimibe (Nustendi®▼) prescribing and adverse event reporting information
BEM/21/0831Date of preparation: December 2021
If you are a UK-based doctor, nurse, or pharmacist, you must sign in to your account or register (for free) if you do not already have one.
Return to homepage
Site powered by Webvision Cloud